Published in Gastroenterology on June 01, 1999
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine | NCT03073343
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest (2004) 3.92
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol (2006) 3.46
Liver enzyme alteration: a guide for clinicians. CMAJ (2005) 3.42
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology (2013) 2.64
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol (2014) 2.39
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med (2012) 2.28
Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol (2012) 2.25
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology (2014) 2.23
Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology (2007) 2.22
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem (2009) 2.13
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Evaluation of abnormal liver function tests. Postgrad Med J (2003) 1.92
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci (2005) 1.80
Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.75
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci (2011) 1.74
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol (2008) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) (2008) 1.64
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Non-invasive means of measuring hepatic fat content. World J Gastroenterol (2008) 1.60
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Glycogen hepatopathy in a 13-year-old male with type 1 diabetes. Ann Saudi Med (2011) 1.59
The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.57
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One (2012) 1.56
The genetics of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.55
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 1.54
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther (2015) 1.54
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut (2004) 1.50
Hepatocellular ballooning in NASH. J Hepatol (2010) 1.48
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol (2011) 1.48
Steatosis as a risk factor in liver surgery. Ann Surg (2007) 1.48
Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. J Hepatol (2014) 1.48
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol (2003) 1.47
Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci (2004) 1.46
Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut (2002) 1.44
Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int (2008) 1.43
Efficacy of herbomineral compounds and pathya (Ayurvedic dietary regime and physical exercise) in the management of Yakṛt Roga (Non-alcoholic fatty liver disease). Anc Sci Life (2015) 1.40
Genetic factors for resistance to diet-induced obesity and associated metabolic traits on mouse chromosome 17. Mamm Genome (2009) 1.38
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Role of free radicals in liver diseases. Hepatol Int (2009) 1.36
Obesity: overview of an epidemic. Psychiatr Clin North Am (2011) 1.33
Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol (2007) 1.31
Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut (2005) 1.30
Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol (2005) 1.30
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One (2012) 1.28
The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci (2007) 1.28
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol (2011) 1.28
Treatment of nonalcoholic fatty liver disease. World J Gastroenterol (2006) 1.27
From fatty liver to fibrosis: a tale of "second hit". World J Gastroenterol (2013) 1.26
Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr (2008) 1.26
Fructose as a key player in the development of fatty liver disease. World J Gastroenterol (2013) 1.26
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (1999) 7.60
Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis (1998) 7.51
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. Arch Intern Med (1991) 3.21
Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut (1999) 2.98
A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Am J Respir Crit Care Med (1999) 2.68
A prospective, multi-center clinical trial of the Taylor intragastric balloon for the treatment of morbid obesity. Am J Gastroenterol (1990) 2.59
Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med (1986) 2.57
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Skin and soft-tissue manifestations of Shewanella putrefaciens infection. Clin Infect Dis (1997) 2.45
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Application of digital image analysis and flow cytometry to enumerate marine viruses stained with SYBR gold. Appl Environ Microbiol (2001) 2.30
Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J Clin Microbiol (1998) 2.24
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry (1999) 2.10
Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol (2001) 2.02
Identification of a disease resistance locus in Arabidopsis that is functionally homologous to the RPG1 locus of soybean. Plant J (1993) 2.01
Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol (2001) 1.93
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem (2000) 1.88
Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer (1996) 1.81
Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol (2001) 1.80
Eosinophilic meningitis caused by Angiostrongylus cantonensis: report of 17 cases. Am J Med (2001) 1.76
The psychosocial impact of donating a kidney: long-term follow-up from a urology based center. J Urol (1997) 1.76
Gross and histologic characteristics of laparoscopic injuries with four different energy sources. Fertil Steril (2001) 1.72
Hepatic iron and nonalcoholic fatty liver disease. Hepatology (1999) 1.70
Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: a preliminary report. Thorax (1996) 1.70
Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther (2012) 1.69
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med (2001) 1.65
Impact of liver transplantation on health-related quality of life. Liver Transpl (2000) 1.52
3' splice site selection in dicot plant nuclei is position dependent. Mol Cell Biol (1993) 1.49
Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol (2001) 1.48
Extent of antibiotic use in Taiwan shown by antimicrobial activity in urine. Lancet (1999) 1.43
An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol (2000) 1.42
Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem (2000) 1.41
Mycoplasma pneumoniae infection complicated by lung abscess, pleural effusion, thrombocytopenia and disseminated intravascular coagulation. Pediatr Infect Dis J (1997) 1.39
Atherosclerotic aneurysm formation in an in situ saphenous vein graft. J Vasc Surg (1994) 1.39
Misleading radiograph. Br Dent J (1991) 1.39
AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) (2003) 1.39
Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med (1990) 1.38
Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology (1983) 1.33
Unusual serum lipoprotein abnormality induced by the vehicle of miconazole. N Engl J Med (1977) 1.32
Should all pregnant women be screened for hepatitis B? Ann Intern Med (1987) 1.31
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2010) 1.31
Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells. Proc Natl Acad Sci U S A (1995) 1.31
Bispectral index monitoring of sedation during endoscopy. Gastrointest Endosc (2000) 1.28
Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70. J Biol Chem (2001) 1.27
High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection (2008) 1.26
Protein kinase C mu is negatively regulated by 14-3-3 signal transduction proteins. J Biol Chem (1999) 1.26
Clinical characteristics of emphysematous pyelonephritis. J Microbiol Immunol Infect (2001) 1.26
Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. Proc Natl Acad Sci U S A (1994) 1.23
Mycotic aneurysm due to Burkholderia pseudomallei. Clin Infect Dis (1998) 1.23
The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg (1999) 1.20
Direct interaction between protein kinase C theta (PKC theta) and 14-3-3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function. Mol Cell Biol (1996) 1.20
Comparison of the BACTEC MGIT 960 and BACTEC 460TB systems for detection of mycobacteria in clinical specimens. Ann Clin Lab Sci (2001) 1.20
Mycotic aneurysm due to non-typhi salmonella: report of 16 cases. Clin Infect Dis (1996) 1.19
Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc Natl Acad Sci U S A (1993) 1.19
Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg (1999) 1.18
Reliability of the Muller maneuver and its association with sleep-disordered breathing. Laryngoscope (2000) 1.18
Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol (2000) 1.17
Regulation of protein kinase Ctheta function during T cell activation by Lck-mediated tyrosine phosphorylation. J Biol Chem (2000) 1.17
Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 1.17
Dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy. Br J Anaesth (1999) 1.14
Pyogenic liver abscess: clinical manifestations and value of percutaneous catheter drainage treatment. J Formos Med Assoc (1990) 1.14
Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol (2000) 1.14
Differential gene expression of livers from ApoE deficient mice. Life Sci (2000) 1.14
c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol (1996) 1.13
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther (2011) 1.12
Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases. J Biol Chem (1998) 1.12
Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol (2000) 1.12
Expression of maize Adh1 intron mutants in tobacco nuclei. Plant J (1993) 1.11
Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol (1991) 1.10
Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Viral Hepat (2008) 1.09
Error-tolerant pooling designs with inhibitors. J Comput Biol (2003) 1.09
Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist (2001) 1.09
Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis (1997) 1.09
Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther (2014) 1.08
The effect of copayments and income on the utilization of medical care by subscribers to Japan's National Health Insurance System. Int J Health Serv (1995) 1.08
Variation in tolerance and virulence in the chestnut blight fungus-hypovirus interaction. Appl Environ Microbiol (2000) 1.07
Implementation of clinical guidelines through an electronic medical record: physician usage, satisfaction and assessment. Int J Med Inform (2001) 1.07
Causal bacteria of pyogenic liver abscess. Taiwan Yi Xue Hui Za Zhi (1989) 1.07
Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein. Toxicol Appl Pharmacol (2006) 1.07
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol (2001) 1.06
Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat (2010) 1.06
Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol (1997) 1.06
Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver (2001) 1.05
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl (2001) 1.05